Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvelisib Maintenance After First-Line Therapy for Peripheral T-Cell Lymphoma
NCT07293403Phase 2Recruiting
- Sponsor
- City of Hope
- Start
- Aug 2026
- Primary completion
- Sep 2028
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of duvelisib in peripheral T-cell lymphoma (PTCL) and Follicular T-cell lymphoma (FTCL), sponsored by City of Hope. Primary endpoint: Progression-Free Survival at 1 year. Started Aug 2026; status: recruiting.
02
Drugs
duvelisib
03
Conditions
peripheral T-cell lymphoma (PTCL)Follicular T-cell lymphoma (FTCL)
Beyond the preview
Go deeper on NCT07293403.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07293403.